524711
VISTAPH
Start SIP
Invest Now
Start SIP in VISTAPH
Performance
- Low
- ₹8
- High
- ₹8
- 52 Week Low
- ₹8
- 52 Week High
- ₹13
- Open Price₹8
- Previous Close₹8
- Volume871
- 50 DMA₹8.72
- 100 DMA₹9.21
- 200 DMA₹9.92
Investment Returns
- Over 1 Month -2.22%
- Over 3 Month -15.44%
- Over 6 Month -25.78%
- Over 1 Year -19.81%
Smart Investing Starts Here Start SIP with Vista Pharmaceuticals for Steady Growth!
Vista Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -7.7
- PEG Ratio
- 0.1
- Market Cap Cr
- 52
- P/B Ratio
- 1.2
- Average True Range
- 0.63
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- -0.12
- RSI
- 48.38
- MFI
- 62.5
Vista Pharmaceuticals Financials
Vista Pharmaceuticals Technicals
EMA & SMA
Current Price
₹8.38
+
0.02
(0.24%)
- Bearish Moving Average 11
- Bullish Moving Average 5
- 20 Day
- ₹8.41
- 50 Day
- ₹8.72
- 100 Day
- ₹9.21
- 200 Day
- ₹9.92
Resistance and Support
8.32
- R3 8.90
- R2 8.69
- R1 8.53
- S1 8.16
- S2 7.95
- S3 7.79
Vista Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-11-13 | Quarterly Results | |
| 2025-08-13 | Quarterly Results | |
| 2025-05-30 | Audited Results | |
| 2025-02-19 | Preferential Issue of shares & Others | Inter-alia, to consider 1. Notice of the EGM for the approval of raising of funds. 2. Other business matters. |
| 2025-02-12 | Quarterly Results |
Vista Pharmaceuticals F&O
About Vista Pharmaceuticals
- NSE Symbol
- VISTAPH
- BSE Symbol
- 524711
- Managing Director
- Mr. Murali Meraga
- ISIN
- INE427C01021
Similar Stocks to Vista Pharmaceuticals
Vista Pharmaceuticals FAQs
Vista Pharmaceuticals share price is ₹8 As on 11 January, 2026 | 15:01
The Market Cap of Vista Pharmaceuticals is ₹51.6 Cr As on 11 January, 2026 | 15:01
The P/E ratio of Vista Pharmaceuticals is -7.7 As on 11 January, 2026 | 15:01
The PB ratio of Vista Pharmaceuticals is 1.2 As on 11 January, 2026 | 15:01
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.